Isabella Ciccone, MPH

New findings presented at the 2025 International Epilepsy Conference indicated that cenobamate may provide benefits beyond seizure control in patients with uncontrolled focal-onset seizures.

Experts discussed strategies to improve LGS clinical trial design, better understand comorbidities in rare epilepsies, and foster collaboration across stakeholders. [WATCH TIME: 5 minutes]

Experts discussed gaps in LGS research, including biomarker development, sleep assessment, and early intervention strategies to improve diagnosis and outcomes for patients. [WATCH TIME: 6 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Experts underscored that stakeholder collaboration, including clinicians, caregivers, and industry partners, can play a critical role in advancing understanding and management of LGS. [WATCH TIME: 3 minutes]

Experts discussed initiatives to standardize data collection, expand registries, and empower families in advancing care for Lennox-Gastaut syndrome. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 5, 2025.

Experts highlighted the need for clearer treatment sequencing and improved transition of care for patients with LGS from childhood to adulthood. [WATCH TIME: 3 minutes]

The vice president of scientific engagement at the Alzheimer's Association discussed new data on amyloid-targeting therapies, expanded diagnostic tools, and emerging clinical guidelines for Alzheimer disease presented at AAIC 2025. [WATCH TIME: 5 minutes]

Bio-Thera Solutions announced that its pivotal trial of BAT4406F, an anti-CD20 monoclonal antibody, for neuromyelitis optica spectrum disorder will close enrollment early after achieving statistically significant efficacy.

Amaal Starling, MD, FAHS, FAAN, associate professor of neurology at Mayo Clinic College of Medicine, shared data recently presented at AHS 2025 showing that eptinezumab extended the time between migraine attacks.

New findings from a randomized trial reported no difference in relapse rates or new T2 lesions between a personalized lifestyle app and a nonpersonalized version for multiple sclerosis.

At AAIC 2025, the associate professor in the Department of Psychiatry at McGill University talked about the strengths and limitations of PET and blood biomarkers for Alzheimer disease. [WATCH TIME: 5 minutes]

The director of the Neuroethics Program at Cleveland Clinic discussed the evolving role of ethics in neurological clinical trials, highlighting skill development, safeguards, and patient-centered decision-making.

The physician assistant specializing in Parkinson disease talked about the shared decision-making process when discussing advanced therapies for movement disorder care with patients. [WATCH TIME: 3 minutes]

The nurse practitioner in the Center for Movement Disorders & Neurorestoration at the University of Florida discussed clinical experiences with deep brain stimulation for atypical MS tremor and PD. [WATCH TIME: 5 minutes]

The director of the Movement Disorders Clinic at Houston Methodist Hospital outlined a stepwise approach for identifying, managing, and treating hallucinations in patients with Parkinson disease. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The director of the Adult Genetic Epilepsy Program at the University of Toronto talked about how to ensure a smooth transition from pediatric to adult epilepsy care for university students. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 29, 2025.

The director of the Norman Fixel Institute for Neurological Diseases at UF Health talked about prevention, understanding disease mechanisms, and creating a patient-centered care model in Parkinson disease. [WATCH TIME: 5 minutes]

A recent Canadian study reported similar trends in polysomnography and positive airway pressure initiation over a decade between patients with Parkinson disease and matched controls.

In a recent study, investigators developed multireceptor antagonist peptides that could block CGRP and PACAP, providing proof-of-concept for a potential new approach to targeting pathways involved in migraine.

Spanning the United Kingdom, the United States, European Union, and Japan, the global phase 3 EMPEROR study of zorevunersen is expected to have a data readout by the end of 2027.

The director of the Norman Fixel Institute for Neurological Diseases at UF Health highlighted the need for equitable, worldwide access to levodopa for patients with Parkinson disease. [WATCH TIME: 6 minutes]

Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 4th Annual Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congress.

Here's some of what is coming soon to NeurologyLive® this week.

At the 2025 ATMRD Congress, a patient advocate living with Parkinson disease emphasized the importance of amplifying patient voices at educational conferences for movement disorders. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 22, 2025.

The professor and chair of neuroscience at UT Southwestern Medical Center discussed how circadian clock genes regulate cellular metabolism and potentially influence headache. [WATCH TIME: 6 minutes]